Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,7175719,absorption half-time,Serum tolazamide levels from the formulation that gave rise to rapid absorption were described by one-compartment model kinetics with a mean absorption half-time of 1.0 hr and an elimination half-life of 4.6 hr.,Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175719/),h,1.0,211599,DB00839,Tolazamide
,7175719,elimination half-life,Serum tolazamide levels from the formulation that gave rise to rapid absorption were described by one-compartment model kinetics with a mean absorption half-time of 1.0 hr and an elimination half-life of 4.6 hr.,Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175719/),h,4.6,211600,DB00839,Tolazamide
,7175719,cumulative relative fraction of dose absorbed,"Marked differences were observed in drug bioavailability from the four tablets, and the mean cumulative relative fraction of dose absorbed was 1.0, 0.42, 0.75, and 0.91 from Formulations A, B, C, and D, respectively.",Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175719/),,1.0,211601,DB00839,Tolazamide
,7175719,cumulative relative fraction of dose absorbed,"Marked differences were observed in drug bioavailability from the four tablets, and the mean cumulative relative fraction of dose absorbed was 1.0, 0.42, 0.75, and 0.91 from Formulations A, B, C, and D, respectively.",Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175719/),,0.42,211602,DB00839,Tolazamide
,7175719,cumulative relative fraction of dose absorbed,"Marked differences were observed in drug bioavailability from the four tablets, and the mean cumulative relative fraction of dose absorbed was 1.0, 0.42, 0.75, and 0.91 from Formulations A, B, C, and D, respectively.",Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175719/),,0.75,211603,DB00839,Tolazamide
,7175719,cumulative relative fraction of dose absorbed,"Marked differences were observed in drug bioavailability from the four tablets, and the mean cumulative relative fraction of dose absorbed was 1.0, 0.42, 0.75, and 0.91 from Formulations A, B, C, and D, respectively.",Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7175719/),,0.91,211604,DB00839,Tolazamide
